Last ¥1,864 JPY
Change Today +17.00 / 0.92%
Volume 1.6M
4911 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

shiseido co ltd (4911) Snapshot

Open
¥1,840
Previous Close
¥1,847
Day High
¥1,874
Day Low
¥1,838
52 Week High
06/24/14 - ¥1,934
52 Week Low
07/12/13 - ¥1,438
Market Cap
745.6B
Average Volume 10 Days
1.9M
EPS TTM
¥65.64
Shares Outstanding
400.0M
EX-Date
09/26/14
P/E TM
28.4x
Dividend
¥20.00
Dividend Yield
1.07%
Current Stock Chart for SHISEIDO CO LTD (4911)

Related News

No related news articles were found.

shiseido co ltd (4911) Related Businessweek News

View More BusinessWeek News

shiseido co ltd (4911) Details

Shiseido Company, Limited produces and sells cosmetics, cosmetics accessories, and toiletries in Japan and internationally. It operates in Domestic Cosmetics Business and Global Business segments. The company also produces and sells health and beauty foods, and over-the-counter drugs; and non-Shiseido-brand products and mail-order products, etc., as well as offers hair care, styling, hair color, and perm products; and amenity goods for facilities, such as hotels. In addition, it operates hair, esthetic, and spa salons; manufactures and markets cosmetic raw materials, medical-use pharmaceuticals, and other products; provides products for beauty salons; and operates restaurants. The company sells its products primarily through voluntary chain, department, drug, general merchandise, cosmetics sales, and convenience stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

33,054 Employees
Last Reported Date: 06/25/14
Founded in 1872

shiseido co ltd (4911) Top Compensated Officers

Chief Officer of International Business Divis...
Total Annual Compensation: ¥51.0M
Senior Advisor
Total Annual Compensation: ¥49.0M
Compensation as of Fiscal Year 2013.

shiseido co ltd (4911) Key Developments

Shiseido Co., Ltd. Signs Licensing Agreement with Zadig & Voltaire

Shiseido Co. Ltd. has signed a licensing agreement with Zadig & Voltaire for the creation, production and world distribution of perfumes under the Zadig & Voltaire brand name for the next 15 years. Beaute and Zadig are based in France. Beaute develops and markets perfumes, while Zadig & Voltaire is a manufacturer of luxury apparel, bags, accessories, watches, shoes and perfumes for men, women and kids.

Shiseido Announces Opening of its New Cell-Processing Facility at Kobe Biomedical Innovation Cluster

RepliCel Life Sciences Inc. announce that its RCH-01 licensing partner, Shiseido, celebrated the opening of its new cell-processing facility at the Kobe Biomedical Innovation Cluster (KBIC) located on Port Island, Japan on May 18, 2014. Dignitaries, physicians, partner companies, and government representatives were in attendance at this important event. Shiseido's facility will focus on the continued research and development, and the commercialization of RepliCel's RCH-01 hair regeneration technology. The KBIC is a complex of medical-related industries located on the 833-hectare man-made island of Port Island in Kobe, Japan. Working in cooperation with academic research institutions, government organisations, and industry, the island has been developed as a focal point for research and development of highly advanced medical technologies with the goal of streamlining processes from research to clinical application and commercialization. Regenerative medicine in Japan is an emerging industry which the government has designated as an important part of its economic reform. Legislative support has come from the introduction of new laws to expedite otherwise lengthy clinical research and trial application processes to promote competitive advantage in the international market. In November 2013, as one of the new economic reform strategies, the Japanese government passed the Regenerative Medicine Law, which ensures safety of regenerative medicine, and approved revisions to its existing Pharmaceutical Affairs Law to improve the timelines for the development of regenerative medicine and to promote commercialization. Shiseido has entered into this field via its licensing agreement with RepliCel and is committed to its advancement and success.

Shiseido Co. Ltd. Reports Consolidated Earnings Results for the Fiscal Year Ended March 31, 2014; Provides Earnings Guidance for the First Half Ending September 2014 and Fiscal Year Ending March 31, 2015; Declares Dividend for the Fiscal Year Ended March 31, 2014; Provides Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2015

Shiseido Co. Ltd. reported consolidated earnings results for the fiscal year ended March 31, 2014. For the period, the company reported net sales increased to 12.4% to JPY 762,047 million compared with JPY 677,727 million a year ago. Operating income increased to 90.6% to JPY 49,644 million compared with JPY 26,045 million a year ago. Ordinary income increase to 81.0% to JPY 51,426 million compared with JPY 28,406 million a year ago. Income before income taxes was JPY 50,427 million compared with loss before income taxes of JPY 6,442 million a year ago. Net income increased to JPY 26,149 million or JPY 65.65 per share compared with net loss of JPY 14,685 million or JPY 36.90 per share a year ago. Net cash provided by operating activities was JPY 84,320 million compared with JPY 42,040 million a year ago. Acquisition of property, plant and equipment was JPY 17,964 million compared with JPY 18,763 million a year ago. Acquisition of intangible assets was JPY 4,393 million compared with JPY 5,755 million a year ago. For the second quarter, the company expects to pay cash dividend of JPY 10.00 per share compared to JPY 10.00 per share a year ago. For the fiscal year ending March 31, 2015, the company expects to pay cash dividend of JPY 10.00 per share compared to JPY 10.00 per share a year ago. The company declared year end dividend of JPY 10.00 per share compared to JPY 25.00 per share a year ago. For the first half ending September 2014, the company expects net sales of JPY 366,000 million, operating income of JPY 14,500 million, ordinary income of JPY 14,500 million, net income of JPY 24,500 million and net income per share of JPY 61.47. For the fiscal year ending March 31, 2015, the company expects net sales of JPY 780,000 million, operating income of JPY 42,000 million, ordinary income of JPY 42,000 million, net income of JPY 38,000 million and net income per share of JPY 95.34.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4911:JP ¥1,864.00 JPY +17.00

4911 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AMOREPACIFIC Group 832,000 KRW +15,000
Avon Products Inc $14.30 USD -0.13
Coty Inc $17.49 USD -0.33
Carlyle Group LP/The $33.21 USD +0.36
View Industry Companies
 

Industry Analysis

4911

Industry Average

Valuation 4911 Industry Range
Price/Earnings 29.0x
Price/Sales 1.0x
Price/Book 2.2x
Price/Cash Flow 29.0x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHISEIDO CO LTD, please visit www.shiseido.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.